ASH 2023 | Improving patient outcomes and extending survival in CLL

Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, discusses the current approaches to improving survival outcomes in patients with chronic lymphocytic leukemia (CLL). Based on data from multiple clinical trials, combination therapies, especially those with a venetoclax-based backbone, show promise for improving the progression-free survival (PFS) and overall survival (OS) of patients when compared to traditionally used chemoimmunotherapy regimens. At present, more data is needed to inform the most optimal strategies for maximizing responses in the front-line treatment of CLL, and the treatment of Richter’s transformation (RT) remains an area of unmet need where further investigation is also required. Additionally, Dr Rhodes highlights that measurable residual disease (MRD)-guided strategies are likely to be important in the future and emphasizes that the recent approval of pirtobrutinib in the third-line setting is a step forward in improving the survival of patients who have previously failed on both a BTK and BCL2 inhibitor. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.